FRMD8 siRNA (h): sc-96500



The Power to Question

BACKGROUND

FERM domains are roughly 150 amino acids in length and are found in a number of cytoskeletal-associated proteins such as Ezrin, Radixin, Moesin and 4.1 (erythrocyte membrane protein band 4.1), where they provide a link between cytoskeletal signals and membrane dynamics. FRMD8 (FERM domain-containing protein 8), also known as FKSG44, is a 464 amino acid protein containing one FERM domain. Existing as two alternatively spliced isoforms, the gene encoding FRMD8 maps to human chromosome 11q13.1. With approximately 135 million base pairs and 1,400 genes, chromosome 11 makes up around 4% of human genomic DNA and is considered a gene and disease association dense chromosome. Wilms' tumors, WAGR syndrome and Denys-Drash syndrome are associated with mutations of the WT1 gene. Jervell and Lange-Nielsen syndrome, Jacobsen syndrome, Niemann-Pick disease, hereditary angioedema and Smith-Lemli-Opitz syndrome are also associated with defects in chromosome 11.

REFERENCES

- Grossfeld, P.D., et al. 2004. The 11q terminal deletion disorder: a prospective study of 110 cases. Am. J. Med. Genet. A 129A: 51-61.
- Zehelein, J., et al. 2006. Skipping of Exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen syndrome. J. Biol. Chem. 281: 35397-35403.
- 3. Loussouarn, G., et al. 2006. KCNQ1 K+ channel-mediated cardiac channelopathies. Methods Mol. Biol. 337: 167-183.
- 4. Taylor, T.D., et al. 2006. Human chromosome 11 DNA sequence and analysis including novel gene identification. Nature 440: 497-500.
- Ataga, K.I., et al. 2007. β-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br. J. Haematol. 139: 3-13.
- Berger, A.C., et al. 2007. The subcellular localization of the Niemann-Pick Type C proteins depends on the adaptor complex AP-3. J. Cell Sci. 120: 3640-3652.
- 7. Lee, J.H. and Paull, T.T. 2007. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26: 7741-7748.
- 8. O'Connor, M.J., et al. 2007. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 26: 7816-7824.

CHROMOSOMAL LOCATION

Genetic locus: FRMD8 (human) mapping to 11q13.1.

PRODUCT

FRMD8 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see FRMD8 shRNA Plasmid (h): sc-96500-SH and FRMD8 shRNA (h) Lentiviral Particles: sc-96500-V as alternate gene silencing products.

For independent verification of FRMD8 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-96500A, sc-96500B and sc-96500C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

FRMD8 siRNA (h) is recommended for the inhibition of FRMD8 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

FRMD8 (E-11): sc-514186 is recommended as a control antibody for monitoring of FRMD8 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz Mounting Medium: sc-24941 or UltraCruz Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor FRMD8 gene expression knockdown using RT-PCR Primer: FRMD8 (h)-PR: sc-96500-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com